Growth Metrics

Capricor Therapeutics (CAPR) Income from Continuing Operations (2016 - 2025)

Capricor Therapeutics has reported Income from Continuing Operations over the past 15 years, most recently at 27134794.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 27134794.0 for Q4 2025, down 287.11% from a year ago — trailing twelve months through Dec 2025 was 101884523.0 (down 152.44% YoY), and the annual figure for FY2025 was 105043946.0, down 159.58%.
  • Income from Continuing Operations for Q4 2025 was 27134794.0 at Capricor Therapeutics, down from 24570541.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for CAPR hit a ceiling of 829093.0 in Q4 2023 and a floor of 27134794.0 in Q4 2025.
  • Median Income from Continuing Operations over the past 5 years was 7526612.5 (2022), compared with a mean of 10732538.15.
  • Biggest five-year swings in Income from Continuing Operations: soared 89.21% in 2023 and later plummeted 745.46% in 2024.
  • Capricor Therapeutics' Income from Continuing Operations stood at 6363658.0 in 2021, then decreased by 20.79% to 7686646.0 in 2022, then soared by 89.21% to 829093.0 in 2023, then plummeted by 745.46% to 7009669.0 in 2024, then tumbled by 287.11% to 27134794.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 27134794.0 (Q4 2025), 24570541.0 (Q3 2025), and 25925782.0 (Q2 2025) per Business Quant data.